EIF5B/mitogen-activated protein kinase 1 axis drives tumor progression and confers dual resistance to chemotherapy and immunotherapy in colonic adenocarcinoma

Table 1 Clinical characteristics of patients with colonic adenocarcinoma from colonic adenocarcinoma clinical specimens, n (%)

Characteristics
Tumor location
Right	40 (57.1)
Left	30 (42.9)
Age (years)
≤ 65	35 (50.0)
> 65	35 (50.0)
Sex
Male	37 (52.9)
Female	33 (47.1)
T stage
T1	5 (7.1)
T2	10 (14.3)
T3	45 (64.3)
T4	10 (14.3)
N stage
N0	41 (58.6)
N1	21 (30.0)
N2	8 (11.4)
M stage
M0	59 (84.3)
M1	11 (15.7)
Grade
Well differentiated	13 (18.6)
Moderately differentiated	45 (64.3)
Poorly differentiated	12 (17.1)
Overall survival
Alive	48 (68.6)
Dead	22 (31.4)

Table 2 Cox regression analysis outcomes for clinical characteristics of colonic adenocarcinoma patients and eukaryotic translation initiation factor 5B expression

Variable		Total (n = 70)	Univariate Cox analysis
			Hazard ratio	95%CI	P value
Tumor location	Right	40
	Left	30	0.408	0.158-1.054	0.064
Age	≤ 65	35
	> 65	35	1.462	0.631-3.388	0.375
Sex	Male	37
	Female	33	1.408	0.608-3.261	0.424
T stage	T1 + T2	15
	T3 + T4	55	7.952	1.638-38.590	0.010
N stage	N0	41
	N1 + N2	29	12.276	3.610-41.747	0.000
M stage	M0	59
	M1	11	3.898	1.535-9.898	0.004
Grade	Well differentiated	13			0.047
	Moderately differentiated	45	4.677	0.617-35.447	0.136
	Poorly differentiated	12	11.287	1.334-95.476	0.026
EIF5B	High (reference)	44
	Low	26	0.203	0.060-0.692	0.011
			Multivariate Cox analysis
Tumor location	Right	40
	Left	30	0.399	0.126-1.263	0.118
T stage	T1 + T2	15
	T3 + T4	55	1.962	0.224-17.189	0.543
N stage	N0	41
	N1 + N2	29	14.023	2.972-66.612	0.001
M stage	M0	59
	M1	11	1.489	0.506-4.389	0.470
Grade	Well differentiated	13			0.888
	Moderately differentiated	45	1.654	0.200-13.680	0.640
	Poorly differentiated	12	1.518	0.147-15.687	0.726
EIF5B	High (reference)	44
	Low	26	0.120	0.029-0.487	0.003

CI: Confidence interval; EIF5B: Eukaryotic translation initiation factor 5B.

Table 3 The correlation between clinical characteristics of colonic adenocarcinoma patients and eukaryotic translation initiation factor 5B expression

Characteristics	n = 70	EIF5B		χ2 value	P value
		Low	High
T stage				4.686	0.030
T1 + T2	15	11	4
T3 + T4	55	23	32
N stage				0.278	0.598
N0	41	21	20
N1 + N2	29	13	16
M stage				0.051	0.822
M0	59	29	30
M1	11	5	6

Table 4 Association between eukaryotic translation initiation factor 5B and immunophenoscore scores using The Cancer Immunome Atlas database

Characteristics	r value	P value
IPS-CTLA-4-negative-PD-1-negative1	-0.128	0.019
IPS-CTLA-4-negative-PD-1-positive2	-0.137	0.012
IPS-CTLA-4-positive-PD-1-negative3	-0.172	0.002
IPS-CTLA-4-positive-PD-1-positive4	-0.189	< 0.001

¹Predicted efficacy under no anti-cytotoxic T lymphocyte-associated antigen-4/anti-programmed cell death protein 1 blockade.

²Predicted efficacy under anti-programmed cell death protein 1 monotherapy.

³Predicted efficacy under anti-cytotoxic T lymphocyte-associated antigen-4 monotherapy.

⁴Predicted efficacy under combined anti-cytotoxic T lymphocyte-associated antigen-4/anti-programmed cell death protein 1 blockade.

CTLA-4: Cytotoxic T lymphocyte-associated antigen-4; IPS: Immunophenoscore; PD-1: Programmed cell death protein 1.